This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Tocilizumab 8mg/kg every 2 weeks given by IV infusion
McMaster Children's Hospital
Hamilton, Ontario, Canada
Efficacy of Tocilizumab
Inhibition of inflammatory markers Improvement in symptoms and signs
Time frame: 2 years
Safety of Tocilizumab
Monitoring of serum lipids and liver function tests
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.